How will therapies evolve as precision biomedicine moves from small clinical trials to everyday care? Building on programmable RNA therapies, targeted gene editing, and patient-tailored nanomedicine manufacturing, this dialogue explores how individualized medicine can be delivered safely and affordably. Participants debate the regulatory, ethical, and access challenges that must be solved to bring a new generation of targeted therapies to patients around the world.

Speakers

• Victor Ambros, Silverman Professor of Natural Sciences, University of Massachusetts Chan Medical School

• Magdalena Skipper, Editor in Chief, Nature, Springer Nature

• Dan Skovronsky, Chief Scientific and Product Officer, Lilly

• Nora Cavani, Founder and CEO, Alba Health

• Dan Vahdat, CEO & Founder, Huma Therapeutics Ltd